CN1833633A - 一种可透血脑屏障的脂质体和以该脂质体为载体的药物组合物及其制备方法 - Google Patents
一种可透血脑屏障的脂质体和以该脂质体为载体的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN1833633A CN1833633A CN 200510120550 CN200510120550A CN1833633A CN 1833633 A CN1833633 A CN 1833633A CN 200510120550 CN200510120550 CN 200510120550 CN 200510120550 A CN200510120550 A CN 200510120550A CN 1833633 A CN1833633 A CN 1833633A
- Authority
- CN
- China
- Prior art keywords
- liposome
- brain barrier
- blood brain
- see
- ngf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 127
- 238000000034 method Methods 0.000 title claims abstract description 39
- 210000004369 blood Anatomy 0.000 title description 19
- 239000008280 blood Substances 0.000 title description 19
- 210000004556 brain Anatomy 0.000 title description 12
- 230000008499 blood brain barrier function Effects 0.000 claims abstract description 70
- 210000001218 blood-brain barrier Anatomy 0.000 claims abstract description 57
- 239000003814 drug Substances 0.000 claims abstract description 38
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 12
- 230000008569 process Effects 0.000 claims abstract description 10
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 6
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 61
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 61
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 42
- 239000000243 solution Substances 0.000 claims description 42
- 239000012528 membrane Substances 0.000 claims description 24
- 150000002632 lipids Chemical class 0.000 claims description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- 210000003169 central nervous system Anatomy 0.000 claims description 21
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 159000000000 sodium salts Chemical class 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 16
- 239000003960 organic solvent Substances 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- 238000000746 purification Methods 0.000 claims description 14
- 238000002390 rotary evaporation Methods 0.000 claims description 14
- 239000008346 aqueous phase Substances 0.000 claims description 11
- 239000012074 organic phase Substances 0.000 claims description 11
- 239000012071 phase Substances 0.000 claims description 10
- 238000000265 homogenisation Methods 0.000 claims description 9
- 230000009467 reduction Effects 0.000 claims description 9
- 238000009834 vaporization Methods 0.000 claims description 9
- 230000008016 vaporization Effects 0.000 claims description 9
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 8
- -1 N-acetyl PHOSPHATIDYL ETHANOLAMINE Chemical class 0.000 claims description 8
- 238000001704 evaporation Methods 0.000 claims description 8
- 230000008020 evaporation Effects 0.000 claims description 8
- 230000004907 flux Effects 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000011049 filling Methods 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 239000011259 mixed solution Substances 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 230000007704 transition Effects 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 6
- 150000003904 phospholipids Chemical class 0.000 claims description 6
- 229960005321 mecobalamin Drugs 0.000 claims description 4
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical group C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 claims description 4
- 235000007672 methylcobalamin Nutrition 0.000 claims description 4
- 239000011585 methylcobalamin Substances 0.000 claims description 4
- 229940053128 nerve growth factor Drugs 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 3
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 3
- 239000000890 drug combination Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000001641 gel filtration chromatography Methods 0.000 claims description 3
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 150000002270 gangliosides Chemical class 0.000 claims description 2
- 238000004255 ion exchange chromatography Methods 0.000 claims description 2
- 238000012423 maintenance Methods 0.000 claims description 2
- 239000012982 microporous membrane Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 abstract description 2
- 239000002131 composite material Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 20
- 230000002490 cerebral effect Effects 0.000 description 12
- 238000005325 percolation Methods 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 7
- 239000008215 water for injection Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 208000035126 Facies Diseases 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 208000015114 central nervous system disease Diseases 0.000 description 4
- 239000012501 chromatography medium Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000000703 high-speed centrifugation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000009738 saturating Methods 0.000 description 3
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 239000013595 supernatant sample Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 239000002676 xenobiotic agent Substances 0.000 description 2
- 230000002034 xenobiotic effect Effects 0.000 description 2
- GDPHPXYFLPDZGH-XBTMSFKCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 GDPHPXYFLPDZGH-XBTMSFKCSA-N 0.000 description 1
- 108700029992 Ala(2)-Arg(6)- enkephalin-Leu Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229910002056 binary alloy Inorganic materials 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000001759 blood-nerve barrier Anatomy 0.000 description 1
- 210000004781 brain capillary Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000011549 displacement method Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229960001479 tosylchloramide sodium Drugs 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000003805 vibration mixing Methods 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
样品 | NGF标准溶液(μg/ml) | 供试品 | ||||
6.25 | 12.5 | 25 | 50 | 100 | ||
A | 18147 | 36470 | 70050 | 121461 | 250101 | 197672 |
考察时间(月) | 1 | 3 | 6 | 12 |
渗漏率(%) | 2.5 | 2.7 | 3.0 | 3.5 |
考察时间(月) | 0.5 | 1 | 2 | 3 |
渗漏率(%) | 4.7 | 5.2 | 8.8 | 17.5 |
考察时间(h) | 0 | 3 | 6 | 12 | 24 |
NGF(ug/ml) | 2.3 | 2.7 | 4.0 | 4.5 | 4.7 |
有机溶剂 | 甲醇 | 氯仿 | 乙醚 |
残留量(ppm) | 17 | 23 | 14 |
时间(h) | 0 | 3 | 6 | 12 | 24 |
NGF溶液(ng/ml)NGF脂质体(ug/ml) | 00 | 4.5127 | 10332 | 15589 | 17760 |
样品 | 125I-NGF脂质体总放射活性(cmp) | 125I-NGF脂质体总放射活性(cmp) | ||||
15min | 30min | 60min | 15min | 30min | 60min | |
血清肝脾脑 | 68779199874665 | 38862433257884 | 10043722316997 | 69331282114458 | 48877498726679 | 39931703343328 |
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005101205508A CN100411610C (zh) | 2005-12-29 | 2005-12-29 | 一种可透血脑屏障的脂质体和以该脂质体为载体的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005101205508A CN100411610C (zh) | 2005-12-29 | 2005-12-29 | 一种可透血脑屏障的脂质体和以该脂质体为载体的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1833633A true CN1833633A (zh) | 2006-09-20 |
CN100411610C CN100411610C (zh) | 2008-08-20 |
Family
ID=37001624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005101205508A Expired - Fee Related CN100411610C (zh) | 2005-12-29 | 2005-12-29 | 一种可透血脑屏障的脂质体和以该脂质体为载体的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100411610C (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102078299A (zh) * | 2011-01-04 | 2011-06-01 | 海南美大制药有限公司 | 胞磷胆碱钠脂质体固体制剂 |
CN102366408A (zh) * | 2011-09-14 | 2012-03-07 | 海南灵康制药有限公司 | 单唾液酸四己糖神经节苷脂钠脂质体注射剂 |
CN106974889A (zh) * | 2017-03-14 | 2017-07-25 | 重庆大学 | 载药神经节苷脂胶束及其制备方法和应用 |
CN114588109A (zh) * | 2020-12-07 | 2022-06-07 | 沈阳药科大学 | 辅酶q10乳剂及其制备方法和用途 |
CN114642634A (zh) * | 2020-12-17 | 2022-06-21 | 中国科学院深圳先进技术研究院 | 一种透血脑屏障载药胶束及其制备方法和应用 |
US11607385B2 (en) | 2017-12-21 | 2023-03-21 | Innomedica Holding Ag | Liposomes comprising sphingomyelin |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
CN100348198C (zh) * | 2003-01-13 | 2007-11-14 | 重庆富进生物医药有限公司 | 单唾液酸四已糖神经节苷脂脂质体复合物制剂 |
CN100423778C (zh) * | 2003-11-25 | 2008-10-08 | 上海复旦张江生物医药股份有限公司 | 用于上载抗肿瘤药物的脂质体载体及其制备方法和应用 |
-
2005
- 2005-12-29 CN CNB2005101205508A patent/CN100411610C/zh not_active Expired - Fee Related
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102078299A (zh) * | 2011-01-04 | 2011-06-01 | 海南美大制药有限公司 | 胞磷胆碱钠脂质体固体制剂 |
CN102078299B (zh) * | 2011-01-04 | 2012-09-26 | 海南美大制药有限公司 | 胞磷胆碱钠脂质体固体制剂 |
CN102366408A (zh) * | 2011-09-14 | 2012-03-07 | 海南灵康制药有限公司 | 单唾液酸四己糖神经节苷脂钠脂质体注射剂 |
CN106974889A (zh) * | 2017-03-14 | 2017-07-25 | 重庆大学 | 载药神经节苷脂胶束及其制备方法和应用 |
US11607385B2 (en) | 2017-12-21 | 2023-03-21 | Innomedica Holding Ag | Liposomes comprising sphingomyelin |
CN114588109A (zh) * | 2020-12-07 | 2022-06-07 | 沈阳药科大学 | 辅酶q10乳剂及其制备方法和用途 |
CN114588109B (zh) * | 2020-12-07 | 2023-09-12 | 沈阳药科大学 | 辅酶q10乳剂及其制备方法和用途 |
CN114642634A (zh) * | 2020-12-17 | 2022-06-21 | 中国科学院深圳先进技术研究院 | 一种透血脑屏障载药胶束及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN100411610C (zh) | 2008-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3270478B2 (ja) | 強化されたドラッグ・デリバリーのためのスフィンゴソーム | |
RU2391966C1 (ru) | Наносистема на основе растительных фосфолипидов для включения биологически активных соединений и способ ее получения (варианты) | |
Gao et al. | Bioorthogonal supramolecular cell-conjugation for targeted hitchhiking drug delivery | |
JP4885715B2 (ja) | イリノテカン製剤 | |
Sou et al. | Selective uptake of surface-modified phospholipid vesicles by bone marrow macrophages in vivo | |
CN100411610C (zh) | 一种可透血脑屏障的脂质体和以该脂质体为载体的药物组合物及其制备方法 | |
CN1857222A (zh) | 多西紫杉醇静脉注射亚微乳剂及其制备方法 | |
BR112020021412A2 (pt) | Composição lipossômica, inalável de liberação prolongada para uso no tratamento de doenças pulmonares | |
CN101653414A (zh) | 多西他赛长循环固体脂质纳米粒及其制备方法 | |
CN1846691A (zh) | 注射用的整合素配体修饰的载抗癌药的长循环脂质体 | |
CN101325947A (zh) | 脂质体组合物 | |
Xiong et al. | Preparation, characterization and evaluation of breviscapine lipid emulsions coated with monooleate–PEG–COOH | |
Benita et al. | Radiopaque liposomes: effect of formulation conditions on encapsulation efficiency | |
Ye et al. | Improved lymphatic targeting: effect and mechanism of synthetic borneol on lymph node uptake of 7-ethyl-10-hydroxycamptothecin nanoliposomes following subcutaneous administration | |
US20210093721A1 (en) | Colloidal particles for use in medicine | |
CN106821987B (zh) | 一种载含酚羟基难溶性药物的脂质体及制备方法和应用 | |
RU2411935C1 (ru) | Фармацевтическая композиция на основе доксорубицина и фосфолипидных наночастиц для лечения онкологических заболеваний | |
Fahr et al. | Liposomal formulations of cyclosporin A: a biophysical approach to pharmacokinetics and pharmacodynamics | |
PH26160A (en) | Pharmaceutical compositions consisting of acylated phospholipids | |
CN100336507C (zh) | 尼莫地平新型纳米脂质体、其前体冻干物及其制备方法 | |
CN1631444A (zh) | 一种以磷脂类成分为成膜材料的超声造影剂组合物及其制备方法 | |
CN107362144B (zh) | 一种鲁拉西酮脑靶向脂质体注射剂及其制备方法 | |
CN112773776B (zh) | 一种载药纳米粒体系 | |
CN103040763B (zh) | 一种盐酸拉贝洛尔脂质体注射剂 | |
CN103415283A (zh) | 包含抗肿瘤活性物质的脂质体制剂、它的制备方法以及包含它的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: WUHAN SCIENCE AND TECHNOLOGY INNOVATION BIO-TECHNO Free format text: FORMER OWNER: WUHAN HAITE BIO-PHARMACEUTICAL CO., LTD. Effective date: 20090918 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090918 Address after: Hanyang hanqiang Wuhan economic and Technological Development Zone, Hubei province Wuhan City Street No. 74 Patentee after: Wuhan science and technology innovation Biological Technology Co Ltd Address before: Hubei Province, Wuhan City, Hanyang economic and Technological Development Zone of Wuhan science and technology park. Patentee before: Wuhan Haite Biological Pharmaceutical Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: SIHUAN BIO INDUSTRY GROUP CO., LTD. Free format text: FORMER OWNER: WUHAN SCIENCE AND TECHNOLOGY INNOVATION BIO-TECHNOLOGY CO., LTD. Effective date: 20100318 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 430056 NO.74, HANQIANG STREET, HANYANG WUHAN ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE, WUHAN CITY, HUBEI PROVINCE TO: 100037 8/F, DONGRUN SHIDAI BUILDING, NO.3, FUWAI AVENUE, XICHENG DISTRICT, BEIJING CITY |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100318 Address after: 100037 Beijing City, Xicheng District Fuwai Street No. 3 Dongrun Times Building 8 Patentee after: Four ring Biological Industry Group Co Ltd Address before: Hanyang hanqiang Wuhan economic and Technological Development Zone of Hubei Province, Wuhan City, 430056 street, No. 74 Patentee before: Wuhan science and technology innovation Biological Technology Co Ltd |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080820 Termination date: 20201229 |
|
CF01 | Termination of patent right due to non-payment of annual fee |